Neurovascular Treatment Articles & Analysis
6 news found
The live-in-tissue analysisTM (LITATM), ahigh content phenotypic analyzer, quantifies treatment-induced changes in the tissue construct’s physiological function and the bio-molecular activities underlying those changes. ...
Milan, January 27, 2022 – InnovHeart s.r.l., a developer of novel Transcatheter Mitral Valve Replacement (TMVR) systems for the treatment of mitral valve disease, announces the closing of its Series C financing with granting an exclusive licensing agreement to Grand Pharmaceutical Group Limited, (Grand Pharma) for its proprietary Saturn device in Greater China. ...
The program will begin with a clinical study into the treatment of carotid artery disease using R-One™, the first robotic platform developed by Robocath, which has been on the market since 2019. This first-generation robotic solution was designed to improve the treatment of cardiovascular disease by enhancing physicians’ movements through increased ...
ByRobocath
Food and Drug Administration (FDA) has approved its Investigational Device Exemption (IDE) application to conduct a U.S. trial for the Contour Neurovascular System™, indicated for the treatment of intracranial aneurysms. ...
Completion of the Series B financing will allow the company to execute on its go-to-market strategy and to complete the planned expansion of its product portfolio, which will include a smaller delivery platform for its recently CE Marked lead product, the Contour Neurovascular System, for the treatment of intracranial aneurysms. The company’s second ...
Food and Drug Administration (FDA) 510(k) clearance of its first family of access catheters, designed to deliver interventional treatments during minimally invasive neurovascular procedures for aneurysms, stroke and other brain blood vessel conditions. ...